NCT03952507View on ClinicalTrials.gov

A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

June 22, 2019

Study Completion Date

June 22, 2019

Conditions
Healthy
Interventions
DRUG

JNJ-64417184 600 (Oral Tablet Formulation)

Participants will receive 600 mg of JNJ-64417184 as oral tablet.

DRUG

JNJ-64417184 (Oral Suspension Formulation)

Participants will also receive JNJ-64417184 600 mg as oral suspension.

Trial Locations (1)

84124

PRA Health Sciences Salt Lake City Clinic, Salt Lake City

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03952507 - A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants | Biotech Hunter | Biotech Hunter